Examining the Impact of Blood Flow Restricted Aerobic Exercise on PGC-1α mRNA Expression in Young Healthy Males

Mitochondrial Biogenesis Clinical Trial

Official title:

Examining the Impact of Acute Blood Flow Restricted Aerobic Exercise on PGC-1α mRNA Expression in Young Healthy Males: A Randomized Cross-over Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03717948
• Other study ID #: BFRNP
• Secondary ID: 402635
• Status: Completed
• Phase: N/A
• Start date: October 1, 2018
• Est. completion date: January 28, 2019

Study information

• Verified date: July 2019
• Source: Queen's University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This crossover study investigates the effects of restricting arterial blood flow during cycling exercise on PGC-1α and its upstream signalling pathways. In a randomized order, participants will exercise once for 30 minutes with restricted blood flow and then will exercise once for 30 minutes with no blood flow restriction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: January 28, 2019
• Est. primary completion date: January 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• 3 hours of physical activity per week

• No previous cycling training

• No concurrent involvement in another training program

• Body mass index < 30 kg/m2

Exclusion Criteria:

• Presence of cardiovascular disease

• Presence of metabolic disease

• Taking regular oral medication

• Current smoker

Related Conditions & MeSH terms

• Mitochondrial Biogenesis

Intervention

Other:
• BFR Exercise
Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
• CTL Exercise
Participants will exercise on a recumbent bike placed on flat ground (CTL).

Locations

Country	Name	City	State
Canada	Queen's University	Kingston	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a) messenger ribonucleic acid (mRNA)	Fold-change in PGC-1a mRNA expression	15 minutes before exercise and 3 hours post-exercise for both exercise sessions
Secondary	Catecholamine concentrations	Catecholamine concentrations in venous blood	15 minutes before exercise and immediately post-exercise for both exercise sessions
Secondary	Total and phosphorylated p38 mitogen-activated protein kinase (MAPK)	Fold change in p38 MAPK phosphorylation	15 minutes before exercise and immediately post-exercise for both exercise sessions
Secondary	Total and phosphorylated acetyl coenzyme A carboxylase (ACC)	Fold change in ACC phosphorylation	15 minutes before exercise and immediately post-exercise for both exercise sessions
Secondary	Total and phosphorylated protein kinase A (PKA)	Fold change in PKA phosphorylation	15 minutes before exercise and immediately post-exercise for both exercise sessions
Secondary	Acetylated p53	Fold change in acetylated p53	15 minutes before exercise and immediately post-exercise for both exercise sessions
Secondary	Blood lactate	Average [lactate] between conditions	During both exercise sessions (lactate); 15 minutes before and immediately after both exercise sessions
Secondary	Heart rate (HR)	Average HR between conditions	During both exercise sessions
Secondary	Revolutions per minute (RPM)	Average RPM between conditions	During both exercise sessions
Secondary	Ratings of perceived exertion (RPE)	Average RPE between conditions	During both exercise sessions
Secondary	Oxygenated and deoxygenated hemoglobin	Average oxygenated and deoxygenated hemoglobin as a percentage of same day max values	During both exercise sessions and up to 10 minutes after (for cuff occlusion)